In recent years, PD-1/PD-L1 immunotherapy has rapidly transformed cancer treatment worldwide and become an important therapeutic option for multiple malignancies, including lung cancer, liver cancer, melanoma, and gastric cancer. As immunotherapy gains wider acceptance among patients, market demand continues to grow. However, alongside this rapid expansion, counterfeit PD-1 drugs have also become an increasingly serious problem.

Some patients, desperate to access treatment, trust low-cost sources or purchase medications through social media, overseas purchasing agents, or unauthorized intermediaries, only to receive counterfeit products with unknown origins. For cancer patients, this not only results in financial loss but may also cause them to miss the best treatment window.

As a company deeply involved in the global compliant oncology drug supply chain for many years, DengYueMed has consistently reminded patients of the importance of carefully evaluating drug purchasing channels. As the global anticancer drug market continues to expand, understanding how to identify legitimate pharmaceutical channels has become a critical issue for both patients and their families.

---

Why Are PD-1 Drugs Frequently Targeted by Counterfeiters?

PD-1 drugs are high-value oncology medications, and some imported products are expensive. In addition, many patients seek cross-border purchasing options, creating opportunities for gray-market sellers.

In the internet era, illegal sellers often exploit patients’ anxiety by promoting products through claims such as “overseas channels,” “internal pricing,” or “hospital connections” to sell medications from unknown sources. Some counterfeit products are even packaged and labeled to closely resemble genuine medications, making them difficult for ordinary patients to identify.

At the same time, the global pharmaceutical supply chain has become increasingly complex, and some unauthorized drug distribution channels have become more active. Certain products may not be entirely fake but could involve failed cold-chain transportation, illegal shipping, or repackaged expired drugs, all of which can affect treatment outcomes and medication safety.

---

What Risks Can Counterfeit PD-1 Drugs Cause?

Many patients believe that as long as the medication “looks real,” purchasing it from an unofficial source may not be a major problem. In reality, the risks associated with counterfeit drugs are far more serious than most people imagine.

First, counterfeit drugs may contain no active ingredients at all. Cancer treatment depends heavily on timing and treatment cycles. If patients use ineffective medications during critical stages, the disease may progress rapidly.

Second, some counterfeit products may contain unknown impurities or incorrect ingredients. In severe cases, they may cause abnormal immune reactions, liver and kidney damage, or serious allergic responses. For cancer patients whose physical condition is already weakened, these risks can be particularly dangerous.

In addition, PD-1 monoclonal antibody drugs require strict storage conditions. Even genuine products may lose efficacy if the cold chain fails during transportation. Some so-called “overseas purchased drugs” may not be entirely counterfeit, but unsafe transportation methods still create major risks.

---

How Can Patients Identify Legitimate Pharmaceutical Channels?

In today’s complex market environment, patients first need to understand an important principle: legitimate anticancer drugs are not simply about being “available,” but about having traceable and verifiable origins.

Legitimate medications can usually provide complete production information, batch numbers, import records, and distribution documentation. If sellers cannot clearly explain the drug source or intentionally avoid discussing procurement channels, patients should remain cautious.

Patients should also be highly suspicious of products priced far below normal market levels. PD-1 drugs involve high research and development costs. Although prices may vary between countries, legitimate products are unlikely to be dramatically cheaper than standard market prices. Many so-called “ultra-low-price imported drugs” carry significant risks.

For patients seeking cross-border access to medications, it is especially important to choose qualified pharmaceutical companies or compliant medical service providers. Legitimate pharmaceutical supply chains usually possess pharmaceutical distribution licenses, professional cold-chain transportation systems, and complete traceability capabilities, rather than relying on private purchasing agents or social media transactions.

---

Does Normal Packaging Mean the Drug Is Safe?

Many patients judge drug authenticity based on packaging, but appearance alone is often insufficient.

In recent years, counterfeit drug packaging technology has become increasingly sophisticated. Some fake products can closely imitate genuine packaging. Certain illegal channels even recycle empty drug vials for refilling, meaning that a normal-looking package does not necessarily guarantee safety.

However, patients can still pay attention to several important details:

• Whether the packaging print quality is clear
• Whether the batch number and expiration date are complete
• Whether translated labels appear professional and standardized
• Whether there are signs of repackaging
• Whether the cold-chain packaging appears professional

If the packaging looks poorly made, the text is blurry, the seal appears unusual, or the transportation clearly does not meet cold-chain standards, patients should exercise extreme caution.

---

Why Is Proper Cold-Chain Transportation So Important?

PD-1 drugs are biological products that require strict temperature control. Most products must be stored and transported at temperatures between 2°C and 8°C.

If the medication is exposed to room temperature for extended periods during transportation, it may lose activity even if the appearance remains unchanged. Some unofficial sellers use standard courier shipping without any temperature monitoring in order to reduce costs.

Legitimate supply chains typically provide complete cold-chain transportation information, including temperature records, professional insulated packaging, and shipment tracking data. This is not only an important guarantee of drug quality but also one of the key differences between legitimate and gray-market channels.

---

Why Are Governments Worldwide Increasing Crackdowns on Counterfeit PD-1 Drugs?

As demand for immunotherapy continues to grow, many countries have strengthened regulation of high-value anticancer drugs. With cross-border drug purchasing becoming increasingly common, counterfeit drugs are spreading more rapidly.

Some criminal organizations specifically imitate popular PD-1 products and distribute them through international logistics networks and social media platforms. Because patients are spread across multiple countries, regulatory enforcement has become more challenging.

As a result, more medical institutions are warning patients not to trust so-called “special overseas drugs” or “private channels.” Compared with price, medication safety and supply transparency are far more important.

---

How Can Patients Reduce Risks as Much as Possible?

For cancer patients, choosing legitimate channels is always more important than seeking lower prices.

Before purchasing medications, patients should first consult professional doctors to confirm whether PD-1 therapy is appropriate for their condition and whether legitimate alternative options exist. Whenever possible, medications should be obtained through hospitals, licensed pharmacies, certified pharmaceutical companies, or compliant international medical service providers.

In addition, patients should retain complete purchasing records, including receipts, batch numbers, and logistics information. If abnormalities are discovered, these records can help support reports to regulatory agencies or medical institutions.

---

Conclusion

PD-1 immunotherapy is reshaping global cancer treatment, but at the same time, counterfeit drugs have become an increasingly serious public health concern.

For patients, the most important issue is not simply the drug price, but whether the medication is legitimate, safe, and traceable. Especially as cross-border pharmaceutical purchasing becomes more common, understanding legitimate pharmaceutical supply chains has become an essential part of ensuring treatment safety.

When facing the growing problem of counterfeit PD-1 drugs, remaining rational and carefully choosing official channels is the best way for patients to protect both their treatment rights and their lives.